Charles Schwab Corp (SCHW) has an average rating of overweight and mean price target of $116.11, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $91.16, Change: $+1.72, Percent Change: +1.92%
Xerox Holdings (XRX) shares rose 12% in Friday trading after alternative investment fund Starteepo Invest acquired 6.6 million shares of the business-equipment maker, representing a 5.05% stake.Starteepo said Friday in a statement it "may engage in discussions with Xerox's management and board of directors regarding the company's business, strategy, capital structure, and opportunities to enhance shareholder value."Price: $2.71, Change: $+0.28, Percent Change: +11.52%
eHealth (EHTH) has introduced a "prudent" three-year financial plan that should lead to mid-teens percentage growth in 2028,RBC Capital Markets said in a Thursday report."We view 2026 as a purposeful bridge year, with the company intentionally pulling back on marketing spend to prioritize cash flow generation and operational restructuring," the report said.The plan includes targets for mid-single digit revenue growth in 2027, driven by Medicare agency business and contribution from ancillary cross-selling with the lifetime advisory model, it said."While valuations sector-wide remain depressed followingpersistency headwinds and muted cash flow conversion, we are encouraged by the relative resiliency of eHealth's receivables," the note said.RBC kept its sector perform rating and $3 price target.Price: $1.75, Change: $-0.03, Percent Change: -1.97%
Natera (NTRA) said Friday the US Food and Drug Administration approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab to treat muscle-invasive bladder cancer.The approval follows phase 3 trial results that showed Signatera molecular residual disease-positive patients treated with immunotherapy achieved improvements in disease-free survival and overall survival, while MRD-negative patients achieved 97% two-year OS with no adjuvant therapy, the company said.Price: $189.00, Change: $-7.91, Percent Change: -4.02%